The article focuses on the evolution of treatment of rectal cancer. It states that neoadjuvant chemoradiotherapy with total mesorectal excision has become a standard treatment for the locally advanced disease in the U.S. and Europe. It mentions that newer generation cytotoxic chemotherapeutics and targeted therapies are currently being incorporated into the testing of new strategies in rectal cancer.